107 related articles for article (PubMed ID: 38730085)
1. Biological characterization of renal masses using immuno-PET.
Gelardi F; Larcher A; Antunovic L; Capitanio U; Salonia A; Chiti A
Eur J Nucl Med Mol Imaging; 2024 May; ():. PubMed ID: 38730085
[No Abstract] [Full Text] [Related]
2. 2-Deoxy-2-[F-18]fluoro-D-glucose-positron emission tomography in characterization of solid renal masses.
Kumar R; Chauhan A; Lakhani P; Xiu Y; Zhuang H; Alavi A
Mol Imaging Biol; 2005; 7(6):431-9. PubMed ID: 16307216
[TBL] [Abstract][Full Text] [Related]
3. Assessment of the diagnostic performance of (18)F-FDG-PET/CT for detection and characterization of solid renal malignancies.
Nakhoda Z; Torigian DA; Saboury B; Hofheinz F; Alavi A
Hell J Nucl Med; 2013; 16(1):19-24. PubMed ID: 23529389
[TBL] [Abstract][Full Text] [Related]
4. Potential role of (124)I-girentuximab in the presurgical diagnosis of clear-cell renal cell cancer.
Smaldone MC; Chen DY; Yu JQ; Plimack ER
Biologics; 2012; 6():395-407. PubMed ID: 23204838
[TBL] [Abstract][Full Text] [Related]
5. Diagnosis and staging of cardiac masses: additional value of CMR with
Mikail N; Males L; Hyafil F; Benali K; Deschamps L; Brochet E; Ehmer C; Driss AB; Saker L; Rossi A; Alkhoder S; Raffoul R; Rouzet F; Ou P
Eur J Nucl Med Mol Imaging; 2022 Jun; 49(7):2232-2241. PubMed ID: 35247063
[TBL] [Abstract][Full Text] [Related]
6. Incidental renal masses on SPECT/CT and PET/CT.
Oldan JD; Khandani AH
Am J Nucl Med Mol Imaging; 2022; 12(3):81-85. PubMed ID: 35874298
[TBL] [Abstract][Full Text] [Related]
7. 89Zr-immuno-PET for imaging of long circulating drugs and disease targets: why, how and when to be applied?
Van Dongen GA; Huisman MC; Boellaard R; Harry Hendrikse N; Windhorst AD; Visser GW; Molthoff CF; Vugts DJ
Q J Nucl Med Mol Imaging; 2015 Mar; 59(1):18-38. PubMed ID: 25517081
[TBL] [Abstract][Full Text] [Related]
8. [
Zettlitz KA; Tsai WK; Knowles SM; Salazar FB; Kobayashi N; Reiter RE; Wu AM
Mol Imaging Biol; 2020 Apr; 22(2):367-376. PubMed ID: 31209779
[TBL] [Abstract][Full Text] [Related]
9. Diagnostic accuracy of
Kim SJ; Lee SW; Pak K; Kim IJ; Kim K
Br J Radiol; 2018 Jun; 91(1086):20170520. PubMed ID: 29327944
[TBL] [Abstract][Full Text] [Related]
10. Expanding the Role of Ultrasound for the Characterization of Renal Masses.
Roussel E; Campi R; Amparore D; Bertolo R; Carbonara U; Erdem S; Ingels A; Kara Ö; Marandino L; Marchioni M; Muselaers S; Pavan N; Pecoraro A; Beuselinck B; Pedrosa I; Fetzer D; Albersen M; On Behalf Of The European Association Of Urology Eau Young Academic Urologists Yau Renal Cancer Working Group
J Clin Med; 2022 Feb; 11(4):. PubMed ID: 35207384
[TBL] [Abstract][Full Text] [Related]
11. Renal Masses Detected on FDG PET/CT in Patients With Lymphoma: Imaging Features Differentiating Primary Renal Cell Carcinomas From Renal Lymphomatous Involvement.
Nicolau C; Sala E; Kumar A; Goldman DA; Schoder H; Hricak H; Vargas HA
AJR Am J Roentgenol; 2017 Apr; 208(4):849-853. PubMed ID: 28095016
[TBL] [Abstract][Full Text] [Related]
12. The Production, Quality Control, and Characterization of ZED8, a CD8-Specific
Gill H; Seipert R; Carroll VM; Gouasmat A; Yin J; Ogasawara A; de Jong I; Phan MM; Wang X; Yang J; Ilovich O; Marik J; Williams SP
AAPS J; 2020 Jan; 22(2):22. PubMed ID: 31900688
[TBL] [Abstract][Full Text] [Related]
13. Recent advances in imaging techniques of renal masses.
Aggarwal A; Das CJ; Sharma S
World J Radiol; 2022 Jun; 14(6):137-150. PubMed ID: 35978979
[TBL] [Abstract][Full Text] [Related]
14. Molecular imaging of platelet-derived growth factor receptor-alpha (PDGFRα) in papillary thyroid cancer using immuno-PET.
Wagner M; Wuest M; Hamann I; Lopez-Campistrous A; McMullen TPW; Wuest F
Nucl Med Biol; 2018 Mar; 58():51-58. PubMed ID: 29367096
[TBL] [Abstract][Full Text] [Related]
15. Immuno-PET: Design options and clinical proof-of-concept.
Lugat A; Bailly C; Chérel M; Rousseau C; Kraeber-Bodéré F; Bodet-Milin C; Bourgeois M
Front Med (Lausanne); 2022; 9():1026083. PubMed ID: 36314010
[TBL] [Abstract][Full Text] [Related]
16. The Role of CT Imaging in Characterization of Small Renal Masses.
Bazzocchi MV; Zilioli C; Gallone VI; Commisso C; Bertolotti L; Pagnini F; Ziglioli F; Maestroni U; Aliprandi A; Buti S; Procopio G; Ascenti G; Martini C; De Filippo M
Diagnostics (Basel); 2023 Jan; 13(3):. PubMed ID: 36766439
[TBL] [Abstract][Full Text] [Related]
17. Preoperative characterisation of clear-cell renal carcinoma using iodine-124-labelled antibody chimeric G250 (124I-cG250) and PET in patients with renal masses: a phase I trial.
Divgi CR; Pandit-Taskar N; Jungbluth AA; Reuter VE; Gönen M; Ruan S; Pierre C; Nagel A; Pryma DA; Humm J; Larson SM; Old LJ; Russo P
Lancet Oncol; 2007 Apr; 8(4):304-10. PubMed ID: 17395103
[TBL] [Abstract][Full Text] [Related]
18. Immuno-PET for Clinical Theranostic Approaches.
Bailly C; Cléry PF; Faivre-Chauvet A; Bourgeois M; Guérard F; Haddad F; Barbet J; Chérel M; Kraeber-Bodéré F; Carlier T; Bodet-Milin C
Int J Mol Sci; 2016 Dec; 18(1):. PubMed ID: 28036044
[TBL] [Abstract][Full Text] [Related]
19. Comparison between computed tomography multislice and high-field magnetic resonance in the diagnostic evaluation of patients with renal masses.
Baldari D; Capece S; Mainenti PP; Tucci AG; Klain M; Cozzolino I; Salvatore M; Maurea S
Quant Imaging Med Surg; 2015 Oct; 5(5):691-9. PubMed ID: 26682139
[TBL] [Abstract][Full Text] [Related]
20. FDG PET characterization of renal masses: preliminary experience.
Goldberg MA; Mayo-Smith WW; Papanicolaou N; Fischman AJ; Lee MJ
Clin Radiol; 1997 Jul; 52(7):510-5. PubMed ID: 9240703
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
